ArticleOphthalmology and therapy2024

Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).

Pedram Hamrah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.